Drug
GS 1179
GS 1179: highest development phase Phase 2, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| GS-1179 NCT07912996 | Phase 2 | HSV-2 Infection |
Latest
No recent events.
Follow GS 1179 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.